Cantor Fitzgerald analyst Carter Gould has adjusted his stance on Amgen (AMGN, Financial), changing the rating from Overweight to Neutral. This change comes as Gould assumes responsibility for monitoring the stock.
Alongside the downgrade, Gould has also reduced the price target for Amgen from $340 to $305, reflecting a more cautious outlook for the company's future performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for Amgen Inc (AMGN, Financial) is $322.04 with a high estimate of $400.00 and a low estimate of $185.00. The average target implies an upside of 17.67% from the current price of $273.68. More detailed estimate data can be found on the Amgen Inc (AMGN) Forecast page.
Based on the consensus recommendation from 33 brokerage firms, Amgen Inc's (AMGN, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Amgen Inc (AMGN, Financial) in one year is $347.00, suggesting a upside of 26.79% from the current price of $273.68. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Amgen Inc (AMGN) Summary page.
